ArticleAntibiotics (Basel, Switzerland)2022
In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Resistance ofPathogens (Basel, Switzerland) · 2025Pooled it
- Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.Antimicrobial agents and chemotherapy · 2025Trial
- Comparative activity of sulbactam and sulbactam/durlobactam against carbapenem-resistant A. baumannii isolates producing OXA-23 or OXA-23 plus PER-1 enzymes.The Journal of antibiotics · 2026Article
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Comparative in vitro analysis of sulbactam-durlobactam against extensively drug resistant (XDR) and non-XDR carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates collected from a tertiary care facility in North India.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A 4-methyl-substituted durlobactam analogue as a potential class-D oxacillinase inhibitor inFrontiers in bioinformatics · 2026Article
- Clonal lineage and biofilm growth shape cefiderocol activity inFrontiers in cellular and infection microbiology · 2026Article
- Relationship between antibiotic resistance and biofilm-forming capacity with RND efflux pumps expression in clinical Acinetobacter baumannii isolates.Archives of microbiology · 2025Article
- Article
- Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.International journal of molecular sciences · 2023Review
- Novel Antimicrobial Agents for Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, the in vitro activity of the sulbactam-durlobactam (SUL-DUR) combination was evaluated against 141 carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.